alexa IL-10 Blockade Increases The Therapeutic Efficacy Of Effector B Cells In Cancer Adoptive Immunotherapy By Modulating Host Cellular And Humoral Antitumor Immunity | 6762
ISSN: 2161-1076

Surgery: Current Research
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

IL-10 blockade increases the therapeutic efficacy of effector B cells in cancer adoptive immunotherapy by modulating host cellular and humoral antitumor immunity

International Conference and Exhibition on Surgery, Anesthesia & Trichology

Qiao Li, Huimin Tao, Qin Pan, Fang Zheng, Martin Egenti and Alfred E. Chang

ScientificTracks Abstracts: Surgery Curr Res

DOI: 10.4172/2161-1076.S1.005

Abstract
The role played by B cells in the host immune response to cancer is complex and controversial.We have reported the antitumor reactivity of adoptively transferred effector B cells in several tumor models. To understand the mechanisms by which B cells mediate tumor regression, we used the spontaneous metastasis 4T1 breast cancer model and IL-10 -/- syngeneic Balb/c mice to generate IL-10 -/- tumor-draining lymph nodes (TDLN). Adoptively transferred IL-10 -/- TDLN B cells mediatedsignificantly more effective antitumor immunity than equal numbers of WT TDLN B cells (p<0.05). Activated IL-10 -/- effector 4T1 TDLN B cells were capable of killing4T1 tumor cellsdirectly in a tumor antigen specific manner in in vitro cytotoxicity assays independent of antibody and complement. Adoptive transfer of IL-10 -/- TDLN B cells resulted in the induction ofhost cellular and humoral antitumor immunity significantly morethan adoptive transfer of WT TDLN B cells (p<0.05).Thiswas evident by significantly shiftedcytokine production (e.g. up-regulated IFN-gamma and IL-2 production by host T cells, but down-regulated IL-10 production by host B cells). In addition, adoptively transferred IL-10 -/- TDLN B cells increasedtheproduction oftumor-reactive IgG which bound to 4T1 tumor cells. Furthermore, IL-10 -/- TDLN B cell infusion significantly increased tumor cell lysis (CTL) activitymediated by host Bcells as well asT cells in an immunologically specific fashion. Ourresults indicate that depletion of IL-10-producing B cell subsets may represent an effective strategy to augment the therapeutic efficacy of TDLN B cells used in adoptive immunotherapy.
Biography

Qiao Li, Ph.D., a Research Assistant Professor in the Department of Surgery at the University of Michigan has had his research focused on tumor immunology and cancer immunotherapy. His work both in preclinical studies and in clinical trials has involved the treatment of different tumors, including patients with advanced melanoma and renal cancers. These treatment approaches utilize various immune strategies, such as T cells, B cells, and dendritic cells as well as targeting of cancer stem cells.

Leave Your Message 24x7
Top